{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:17Z","timestamp":1793924477385,"version":"4.8.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of tumor-mediated immune evasion. The frequency of its use has increased rapidly and has extended to numerous cancers. ICIs target immune checkpoint molecules, such as programmed cell death protein 1 (PD-1), PD ligand 1 (PD-L1), and T cell activation, including cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). However, ICI-driven alterations in the immune system can induce various immune-related adverse events (irAEs) that affect multiple organs. Among these, cutaneous irAEs are the most common and often the first to develop. Skin manifestations are characterized by a wide range of phenotypes, including maculopapular rash, psoriasiform eruption, lichen planus-like eruption, pruritus, vitiligo-like depigmentation, bullous diseases, alopecia, and Stevens-Johnson syndrome\/toxic epidermal necrolysis. In terms of pathogenesis, the mechanism of cutaneous irAEs remains unclear. Still, several hypotheses have been proposed, including activation of T cells against common antigens in normal tissues and tumor cells, increased release of proinflammatory cytokines associated with immune-related effects in specific tissues\/organs, association with specific human leukocyte antigen variants and organ-specific irAEs, and acceleration of concurrent medication-induced drug eruptions. Based on recent literature, this review provides an overview of each ICI-induced skin manifestation and epidemiology and focuses on the mechanisms underlying cutaneous irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1071983","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:24:55Z","timestamp":1676877895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":116,"title":["Cutaneous manifestations associated with immune checkpoint inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Tomoya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors I melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/s12885-019-5785-z","article-title":"The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1\/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2020.02.008","article-title":"Immune-mediated adverse effects of immune checkpoint inhibitors and their management in cancer","volume":"221","author":"Jin","year":"2020","journal-title":"Immunol Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jid.2021.06.026","article-title":"Differential involvement of programmed cell death ligands in skin immune responses","volume":"142","author":"Tanaka","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s42003-021-02111-3","article-title":"PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment","volume":"4","author":"Takehara","year":"2021","journal-title":"Commun Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/35105024","article-title":"T-Cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8372.e7","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"303.e10","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(\u00fe)CD4(\u00fe) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020284","article-title":"Mechanism- and immune landscape-based ranking of therapeutic responsiveness of 22 major human cancers to next generation anti-CTLA-4 antibodies","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00354.x","article-title":"Antibody responses to melanoma\/melanocyte autoantigens in melanoma patients","volume":"111","author":"Huang","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"adv00377","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10875-012-9683-2","article-title":"Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity","volume":"32","author":"Zhou","year":"2012","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13567","article-title":"Upregulation of granzyme b and interferon-\u03b3 mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: A case report","volume":"30","author":"Anegawa","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human b-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952099","article-title":"Association between germ-line HLA and immune-related adverse events","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2020.06.011","article-title":"Cutaneous immune-related adverse events to checkpoint inhibitors","volume":"38","author":"Malviya","year":"2020","journal-title":"Clin Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: Pathogenesis, treatment, and surveillance","volume":"20","author":"Bhardwaj","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: A systemic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.308","article-title":"Patterns of response to anti-PD-1 treatment: An exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients","volume":"115","author":"Khoja","year":"2016","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: A predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S364243","article-title":"Skin manifestation induced by immune checkpoint inhibitors","volume":"15","author":"Yamamoto","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Im- mune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for a patient with mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12658","article-title":"Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome","volume":"125","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"APMIS"},{"key":"B56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/PTT.S126727","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore","year":"2019","journal-title":"Eur J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: A detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response","volume":"49","author":"Curry","year":"2019","journal-title":"J Cutan Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine","volume":"24","author":"Fixsen","year":"2019","journal-title":"Oncologist"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1915279","article-title":"Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion","volume":"20","author":"Lommerts","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of antiprogrammed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1177\/2054270418793029","article-title":"Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma","volume":"9","author":"Hanley","year":"2018","journal-title":"JRSM Open"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14043","article-title":"Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab","volume":"45","author":"Kuwatsuka","year":"2018","journal-title":"J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13700","article-title":"Linear bullous lichen planus associated with nivolumab","volume":"44","author":"Biolo","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/programmed death-ligand 1: A case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16036","article-title":"Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms","volume":"34","author":"F\u00e4ssler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13970","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid","volume":"57","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.5070\/D32412042449","article-title":"PD-1 inhibitor induced alopecia areata","volume":"24","author":"Guidry","year":"2018","journal-title":"Dermatol Online J"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14171","article-title":"Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review","volume":"33","author":"Antoury","year":"2020","journal-title":"Dermatol Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: an appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1101a155","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: A literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics","volume":"155","author":"Phillips","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus associated with targeted anticancer therapies and their management","volume":"36","author":"Wu","year":"2018","journal-title":"Dermatol Clin"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.597761","article-title":"The roles of immunoregulatory networks in severe drug hypersensitivity","volume":"12","author":"Hsu","year":"2021","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07023.x","article-title":"The CD40\/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"154","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.017","article-title":"Nivolumab associated DRESS syndrome: a case report","volume":"5","author":"Lu","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLos One"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: An Italian melanoma intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"key":"B105","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","volume":"35","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B106","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw543","article-title":"Pembrolizumab induced severe sclerodermoid reaction","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: A case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J Cutan Pathol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14492","article-title":"Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma","volume":"46","author":"Cho","year":"2019","journal-title":"J Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and non-cutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.050","article-title":"Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors","volume":"87","author":"Hirotsu","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1071983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:24:58Z","timestamp":1676877898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1071983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":115,"alternative-id":["10.3389\/fimmu.2023.1071983"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1071983","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"article-number":"1071983"}}